Impact of Amino Acid Mutations in PB2, PB1-F2, and NS1 on the Replication and Pathogenicity of Pandemic (H1N1) 2009 Influenza Viruses
|
|
- Clemence Oliver
- 5 years ago
- Views:
Transcription
1 JOURNAL OF VIROLOGY, May 2011, p Vol. 85, No X/11/$12.00 doi: /jvi Copyright 2011, American Society for Microbiology. All Rights Reserved. Impact of Amino Acid Mutations in PB2, PB1-F2, and NS1 on the Replication and Pathogenicity of Pandemic (H1N1) 2009 Influenza Viruses Makoto Ozawa, 1,2 Sarmila Basnet, 1 Lisa M. Burley, 1 Gabriele Neumann, 1 Masato Hatta, 1 * and Yoshihiro Kawaoka 1,2,3,4 * Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin 1 ; International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo, Japan 2 ; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo, Japan 3 ; and ERATO Infection-Induced Host Responses Project, Japan Science and Technology Agency, Saitama, Japan 4 Received 5 January 2011/Accepted 7 February 2011 Here, we assessed the effects of PB1-F2 and NS1 mutations known to increase the pathogenicity of influenza viruses on the replication and pathogenicity in mice of pandemic (H1N1) 2009 influenza viruses. We also characterized viruses possessing a PB1-F2 mutation that was recently identified in pandemic (H1N1) 2009 influenza virus isolates, with and without simultaneous mutations in PB2 and NS1. Our results suggest that some NS1 mutations and the newly identified PB1-F2 mutation have the potential to increase the replication and/or pathogenicity of pandemic (H1N1) 2009 influenza viruses. Although the pandemic (H1N1) 2009 influenza A viruses that emerged in the early spring of 2009 circulate widely (4), most infected individuals experience an uncomplicated upper respiratory disorder. These clinical manifestations indicate that the pathogenicity of the pandemic (H1N1) 2009 viruses in most humans is relatively mild, possibly due to preexisting cross-reactive immunity as exemplified by an appreciable immune response upon a single vaccination (7, 20, 28). Nevertheless, these viruses are clearly more pathogenic than seasonal influenza viruses in animal models (11, 16, 18) and in some humans (13). Moreover, their sustained transmission among humans may lead to the emergence of more pathogenic mutants, as has been suggested for the 1918 influenza pandemic virus (25). PB1-F2, which is carried on a 1 reading frame of the gene segment for influenza viral RNA polymerase subunit PB1 (1), is a known virulence factor (3, 17, 27). Specifically, an asparagine-to-serine substitution at position 66 (F2-N66S), which is found in 1918 pandemic viruses, is partly responsible for the high pathogenicity of this virus (3). Most pandemic (H1N1) 2009 viruses, however, possess three stop codons in the region encoding amino acid positions 12, 58, and 88 in the PB1-F2 reading frame and, therefore, do not express full-length PB1- * Corresponding author. Mailing address for Masato Hatta: Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 575 Science Drive, Madison, WI Phone: (608) Fax: (608) mhatta@facstaff.wisc.edu. Mailing address for Yoshihiro Kawaoka: Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 575 Science Drive, Madison, WI Phone: (608) Fax: (608) kawaokay@svm.vetmed.wisc.edu. These authors contributed equally to this work. Published ahead of print on 16 February F2. Hai et al. (8) demonstrated that pandemic (H1N1) 2009 viruses possessing full-length PB1-F2 with or without F2-N66S do not exhibit increased in vitro and in vivo growth kinetics or mouse pathogenicity; however, the phenotype of viruses possessing shorter PB1-F2 proteins (i.e., of 57 or 87 amino acids) has not been studied. Such studies have become even more relevant with the recent isolation of three pandemic (H1N1) 2009 virus isolates (A/Wisconsin/629-D00485/2009 [GenBank accession number CY057428], A/Wisconsin/629-D00832/2009 [GenBank accession number CY057412], and A/Puerto Rico/ 51/2009 [GISAID { struktur.jdante?aid 1131} accession number EPI252209]) with a stop-to-leucine substitution at position 12 in the PB1-F2 (F2-stop12L) protein, hence creating a PB1-F2 protein of 57 amino acids in length. NS1 is an influenza viral interferon antagonist (6). Its C-terminal four residues in most humans and several animal isolates possess an X-S/T-X-V-type PDZ ligand motif (21), which modulates protein-protein interactions in a sequence-specific fashion (22). These four residues are also thought to influence mouse pathogenicity (12). However, the pandemic (H1N1) 2009 viruses possess a truncated NS1 protein due to a stop codon in the region encoding amino acid position 220. Moreover, elimination of the stop codon would result in an NS1 protein carrying GTEI at positions 227 to 230, which deviates from the X-S/T-X-V-type PDZ ligand motifs. Hale et al. (9) characterized a pandemic (H1N1) 2009 virus that possesses the full-length NS1 protein carrying GTEI at positions 227 to 230 in vitro and in vivo: however, the effect of the PDZ ligand motifs on the pathogenicity of this virus remains unknown. Here, we assessed the impact of PB1-F2 and NS1 mutations that are known to increase the pathogenicity of influenza viruses on the replication and pathogenicity in mice of pandemic (H1N1) 2009 influenza viruses. We also examined the pheno- 4596
2 VOL. 85, 2011 NOTES 4597 FIG. 1. Schematic diagrams of the wild-type and mutant genes tested in this study. (A) PB1-F2 variants. Black bars represent stop codons in the regions encoding positions 12, 58, and 88. Red bars represent the stop12s, stop58w, and stop88w substitutions. Green bars represent the N66S substitution. The blue bar represents the stop12l substitution. The number of amino acids for each PB1-F2 variant is indicated to the right of the bars. (B) NS1 variants. The black bars represent a stop codon in the region encoding position 220. W and R represent the stop220w and stop220r substitutions, respectively. GTEI, RSEV, RSKV, KSEV, and ESEV represent the C-terminal four residues of NS1. The number of amino acids for each NS1 variant is indicated to the right of the bars. type of viruses possessing the newly identified F2-stop12L mutants with and without mutations known to affect pathogenicity in the viral RNA polymerase subunit PB2 and in NS1. To assess the effect of PB1-F2 mutations on the replication and pathogenicity of pandemic (H1N1) 2009 viruses, we performed reverse genetics (19) to generate A/California/04/09 (H1N1; CA04) mutants possessing one of the following single or multiple mutations in the PB1-F2 reading frame: (i) a stopto-serine substitution at position 12 (F2-stop12S) (note that the F2-stop12S mutants were generated and tested before natural isolates with a leucine at this position were reported; serine was chosen at that time because this mutation does not affect the PB1 amino acid composition); (ii) F2-stop12S and a stop-to-tryptophan substitution at position 58 (F2-stop58W); (iii) F2-stop12S, F2-stop58W, and a stop-to-tryptophan substitution at position 88 (F2-stop88W); (iv) F2-stop12S, F2-stop58W, and F2-N66S (F2-stop58W/N66S); and (v) F2- stop12s, F2-stop58W, F2-N66S, and F2-stop88W (F2- stop88w/n66s) (Fig. 1A). None of these PB1-F2 mutations changes the PB1 amino acid composition. The F2-stop88W and F2-stop88W/N66S mutants are identical to the mutants assessed by Hai et al. (8). To determine the in vitro growth kinetics of these PB1-F2 mutants, we infected MDCK cells with viruses at a multiplicity of infection (MOI) of Supernatants of the infected cells were harvested at 12, 24, 48, and 72 h postinfection (p.i.) and subjected to plaque assays for virus titration. No substantial differences were observed in in vitro growth kinetics between wild-type and mutant viruses (Fig. 2A). Further, to assess the mouse pathogenicity of these CA04 PB1-F2 mutants, three mice (6-week-old female BALB/c mouse; Jackson Laboratory, Bar Harbor, ME) per FIG. 2. In vitro growth kinetics of CA04 mutants. MDCK cells were infected with wild-type CA04 (A to D), PB1-F2 mutants (A), NS1 mutants possessing stop220w (B), NS1 mutants possessing stop220r (C), or PB2, PB1-F2, and NS1 combination mutants (D) at an MOI of At the indicated time points postinfection, the virus titers in the cell culture supernatants were assessed by using plaque assays. Error bars indicate the standard deviations (SD) of results from triplicate infections.
3 4598 NOTES J. VIROL. FIG. 3. Body weight changes in mice infected with CA04 mutants. BALB/c mice were infected with 10 5 PFU of wild-type CA04 (A to D), PB1-F2 mutants (A), NS1 mutants possessing stop220w (B), NS1 mutants possessing stop220r (C), or PB2 mutants (D). Body weights were monitored daily. Error bars indicate the SD of results from triplicate infections. Data in panel D have been published previously (26) but are presented here for comparison. group were intranasally inoculated with 10 5 PFU (50 l) of virus and monitored daily for 14 days for changes in body weight. None of the virus-infected mice exhibited severe weight loss during the monitoring period (Fig. 3A). Hai et al. (8) also found that the F2-stop88W and F2-stop88W/N66S mutants were comparable to the wild-type virus in terms of replication in MDCK cells and mouse pathogenicity. These results indicate that the PB1-F2 mutations tested had limited effect on the in vitro growth kinetics and pathogenicity of pandemic (H1N1) 2009 viruses. We also assessed the effect of NS1 mutations on virus replication and pathogenicity of pandemic (H1N1) 2009 viruses by using reverse genetics-derived CA04 mutants with one of the following NS1 mutations: (i) a stop-to-tryptophan substitution at position 220 (NS1-stop220W) (tryptophan is commonly observed at this position in the classical swine virus lineage whose NS gene is an ancestor of that of the pandemic [H1N1] 2009 virus [4]; note that this mutation results in a glutamic acid-toglycine substitution at position 63 in another protein encoded by the NS gene, NS2); (ii) NS1-stop220W and a C-terminal GTEI-to-RSEV substitution (creating a seasonal H1N1 virustype PDZ ligand motif) (NS1-W-RSEV); (iii) NS1-stop220W and a GTEI-to-RSKV substitution (creating a seasonal H3N2 virus-type PDZ ligand motif) (NS1-W-RSKV); (iv) NS1- stop220w and a C-terminal GTEI-to-KSEV substitution (creating a 1918 pandemic virus-type PDZ ligand motif) (NS1-W-KSEV); and (v) NS1-stop220W and a C-terminal GTEI-to-ESEV substitution (creating a highly pathogenic H5N1 virus-type PDZ ligand motif) (NS1-W-ESEV) (Fig. 1B). While the KSEV and ESEV mutations resulted in a glycineto-serine substitution at position 70 in NS2 (as found in 1918 pandemic and H5N1 viruses), the remaining PDZ ligand motif mutations did not change the NS2 amino acid composition. Further, we prepared additional versions of these NS1 mutants with a stop-to-arginine substitution at position 220 (NS1- stop220r), which is found in most of human isolates and does not change the NS2 amino acid composition, i.e., NS1- stop220r, NS1-R-RSEV, NS1-R-RSKV, NS1-R-KSEV, and NS1-R-ESEV (Fig. 1B). The NS1-stop220R mutant is identical to one of the mutants assessed by Hale et al. (9). Consistent with the earlier report that the NS1-stop220W mutant replicates comparably to wild-type virus in primary differentiated human tracheobronchial epithelial cells and a swine cell line (9), its growth kinetics in MDCK cells was also comparable to that of wild-type virus; however, different PDZ ligand motifs at the C terminus of NS1 affected virus replication to some extent (Fig. 2B). Interestingly, the three mutants that exhibited slightly increased titers compared to wild-type virus at 48 and 72 h p.i., NS1-W-RSEV, -KSEV, and -ESEV, share the amino acid sequence SEV at the last three residues of the PDZ ligand motif. In contrast, the SEV motif at the three C-terminal amino acids of NS1 did not increase viral replication in the context of NS1-stop220R (Fig. 2C). These results indicate that the X-S-E-V PDZ ligand motif in NS1 contributes to the efficient replication of pandemic (H1N1) 2009 viruses in cell culture in concert with a tryptophan, but not an arginine, at position 220. In mice intranasally inoculated with 10 5 PFU (50 l) of virus, the NS1-W-RSEV, -RSKV, and -ESEV mutants exhibited higher pathogenicity, as measured by body weight loss, than the wild-type virus (Fig. 3B). The mouse pathogenicity of the three mutants, NS1-W-RSEV, -RSKV, and -ESEV, was tested further by infecting animals with different doses of virus (10 4,10 5,or10 6 PFU) (Fig. 4A to C and data not shown). In animals infected with 10 4 and 10 5 PFU of virus, all three mutants caused slightly more weight loss than was caused by the wild-type virus. More importantly, all mice infected with 10 6 PFU of NS1-W-RSKV died by day 5 p.i. (Fig. 4C), in contrast to animals infected with the wild type and the other two mutant viruses; these data confirm the substantially increased pathogenicity of the NS1-W-RSKV mutant. In contrast, NS1-R-RSEV and -RSKV were attenuated in mice (Fig. 3C). The remaining NS1 mutants were comparable to wildtype virus in their pathogenicity in mice (Fig. 3B and C). The pathogenicity in mice of NS1-stop220R as reported by Hale et al. (9) was comparable to that shown in Fig. 3C. To determine the in vivo virus replication levels of NS1 mutants, six mice per group were intranasally infected with 10 5 PFU of each mutant and three mice per group were euthanized on days 3 and 6 p.i. NS1 mutants possessing NS1- stop220w were comparable to wild-type virus in their replicative ability in mouse organs (Table 1). In contrast, the NS1 mutants possessing NS1-stop220R replicated poorly in mice
4 VOL. 85, 2011 NOTES 4599 FIG. 4. Body weight changes in mice infected with CA04 NS1 and PB2, PB1, and NS1 combination mutants. BALB/c mice were infected with 10 4 (A, D), 10 5 (B, E), or 10 6 (C, F) PFU of wild-type CA04 (A to F), the NS1-W-RSKV mutant (A to C), the PB2-E627K F2-stop12L NS1- W-RSKV mutant (D to F), or the PB2-D701N F2-stop12L NS1-W-RSKV mutant (D to F). Body weights were monitored daily. Mice with body weight loss of more than 25% of their preinfection value were euthanized. Error bars indicate SD of results from triplicate infections. Downloaded from compared to wild-type virus (Table 1), consistent with our earlier finding that these mutants cause less severe weight loss in mice than did wild-type virus. Hale et al. (9) also reported that the replication of NS1-stop220R was slightly impaired in mouse lungs. Collectively, these results indicate that the PDZ ligand motifs RSEV, RSKV, and ESEV, in combination with a tryptophan at position 220 in NS1, increase the mouse pathogenicity of a pandemic (H1N1) 2009 virus, although they do not substantially increase in vitro and in vivo virus replication. In the spring of 2010, three pandemic (H1N1) 2009 viruses possessing F2-stop12L, which does not change the PB1 amino acid composition, were isolated. We evaluated the effect of this mutation with or without an NS1 mutation that exhibits increased pathogenicity in mice (NS1-W-RSKV) and one of the following two PB2 mutations: a glutamic acid-to-lysine change at position 627 (PB2-E627K) or an aspartic acid-to-asparagine substitution at position 701 (PB2-D701N). These two mutations are involved in adaptation (2, 5, 14, 24) and increased pathogenicity (10, 15, 23) of avian-origin influenza viruses to mammalian hosts. To this end, we generated CA04 mutants possessing the following mutations: (i) F2-stop12L (Fig. 1A); (ii) PB2-E627K, F2-stop12L, and NS1-W-RSKV (PB2- E627K F2-stop12L NS1-W-RSKV); and (iii) PB2-D701N, F2-stop12L, and NS1-W-RSKV (PB2-D701N F2- stop12l NS1-W-RSKV). We found that all three mutants possessing the F2-stop12L mutation replicated more efficiently in MDCK cells than did wild-type virus (Fig. 2D), in contrast to the F2-stop12S mutant, which was comparable in its replicative ability to wild-type virus (Fig. 2A). These findings indicate that F2-stop12L promotes the in vitro replication of pandemic (H1N1) 2009 viruses. However, we did not observe any synergistic effect of NS1-W-RSKV and PB2-E627K or PB2-D701N on in vitro replication. Next, we tested the weight loss of mice infected with the above-described mutants. While the weight loss of mice infected with the F2-stop12L mutant was comparable to that of mice infected with wild-type virus, the two combination mutants PB2-E627K F2-stop12L NS1-W-RSKV and PB2- D701N F2-stop12L NS1-W-RSKV caused increased pathogenicity in mice infected with 10 6 PFU (Fig. 4D to F), as has been reported with mutant viruses possessing either PB2- E627K or PB2-D701N alone (Fig. 2D) (26). These combination mutants, however, did not kill mice even at 10 6 PFU, although the mutant virus possessing only NS1-W-RSKV exhibited mouse lethality (Fig. 4C); this finding suggests potential attenuating effects of the additional mutations in the viral background tested here. No significant differences in virus titers in mouse organs were observed between wild-type virus and the mutants tested (Table 1). Thus, F2-stop12L increases the replicative ability of pandemic (H1N1) 2009 viruses in cell culture, although an increase in mouse pathogenicity was not detectable. In this study, we assessed the effects of previously identified pathogenic mutations in PB1-F2 and NS1 and of a recently identified PB1-F2 mutation and the synergistic effects of some on August 19, 2018 by guest
5 4600 NOTES J. VIROL. TABLE 1. Virus titers in organs of mice infected with CA04 mutants a Virus Day postinfection Virus titer (mean log 10 no. of PFU SD/g) in: Lungs Nasal turbinates NS1-stop220W NS1-W-RSEV NS1-W-RSKV NS1-W-KSEV NS1-W-ESEV NS1-stop220R NS1-R-RSEV NS1-R-RSKV NS1-R-KSEV NS1-R-ESEV F2-stop12L PB2-E627K F stop12l NS-RSKV 6 4.8, PB2-D701N F , 6.3 stop12l NS-RSKV 6 3.5, Wild-type a Six-week-old BALB/c mice, anesthetized with isoflurane, were infected intranasally with 50 l of virus (10 5 PFU). Three mice from each infected group were sacrificed on days 3 and 6 postinfection for virus titration. When virus was not recovered from all three mice, individual titers were recorded. of these mutations on the replication and mouse pathogenicity of pandemic (H1N1) 2009 influenza viruses. As previously reported (8, 9), F2-stop88W, F2-stop88W/ N66S, and NS1-stop220R mutations did not increase the replication and pathogenicity of pandemic (H1N1) 2009 influenza viruses (Fig. 2A and C and 3A and C). In contrast, our results show that NS1 mutants possessing stop220w in combination with an XSEV PDZ ligand motif (Fig. 2B), and the F2-stop12L mutant (Fig. 2D), replicated in MDCK cells more efficiently than did the wild-type virus. Further, NS1-W-RSEV, -RSKV, and -ESEV mutants exhibited increased pathogenicity in mice (Fig. 3B and 4A to C), while the virus titers in respiratory organs were comparable to those of the wild-type virus (Table 1). Interestingly, the PDZ ligand motif RSKV of seasonal H3N2 viruses, which are less pathogenic than the 1918 pandemic virus or highly pathogenic H5N1 viruses, conferred the highest pathogenicity in mice among the PDZ motives tested (Fig. 4A to C). These results suggest that the effect of the NS1 PDZ ligand motif on pathogenicity may differ depending upon the context of the viral gene backbone. In fact, the introduction of ESEV into the C terminus of the NS1 protein of the highly pathogenic A/Vietnam/1203/04 (H5N1) virus, whose NS1 protein does not possess the PDZ ligand motif, decreases mouse pathogenicity (29). No synergistic effects of F2-stop12L, NS1- W-RSKV, and PB2-E627K or PB2-D701N were observed in cell culture (Fig. 2D) or in mice (Fig. 4D to F and Table 1). The mouse pathogenicity of the two combination mutants (PB2-E627K F2-stop12L NS1-W-RSKV and PB2- D701N F2-stop12L NS1-W-RSKV) may have been impaired compared to that of the NS1-W-RSKV mutant (Fig. 3B and 4A to C) because the F2-stop12L mutation may decrease the mouse pathogenicity of pandemic (H1N1) 2009 influenza viruses. In fact, the pathogenicity of the F2-stop12L mutant was slightly decreased compared to that of the wild-type virus in mice infected with 10 6 PFU of virus (Fig. 4D to F). Although some mutations affected replication but not pathogenicity or vice versa, these results show that certain mutations in NS1 and PB1-F2 can impact the pathogenicity of pandemic (H1N1) 2009 influenza viruses. We thank Susan Watson for editing the manuscript. This work was supported by ERATO (Japan Science and Technology Agency), by a grant-in-aid for Specially Promoted Research from the Ministries of Education, Culture, Sports, Science, and Technology, by grants-in-aid from Health, Labor, and Welfare of Japan, by a Contract Research Fund for the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases, by National Institute of Allergy and Infectious Disease Public Health Service research grants, and by an NIAID-funded Center for Research on Influenza Pathogenesis (CRIP, HHSN C). REFERENCES 1. Chen, W., et al A novel influenza A virus mitochondrial protein that induces cell death. Nat. Med. 7: Clements, M. L., et al Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers. J. Clin. Microbiol. 30: Conenello, G. M., D. Zamarin, L. A. Perrone, T. Tumpey, and P. Palese A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog. 3: Dawood, F. S., et al Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360: Gabriel, G., et al Differential polymerase activity in avian and mammalian cells determines host range of influenza virus. J. Virol. 81: Garcia-Sastre, A., et al Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252: Greenberg, M. E., et al Response to a monovalent 2009 influenza A (H1N1) vaccine. N. Engl. J. Med. 361: Hai, R., et al PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models. J. Virol. 84: Hale, B. G., R. E. Randall, J. Ortin, and D. Jackson The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 89: Hatta, M., P. Gao, P. Halfmann, and Y. Kawaoka Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293: Itoh, Y., et al In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: Jackson, D., M. J. Hossain, D. Hickman, D. R. Perez, and R. A. Lamb A new influenza virus virulence determinant: the NS1 protein four C-terminal residues modulate pathogenicity. Proc. Natl. Acad. Sci. U. S. A. 105: Jain, S., et al Hospitalized patients with 2009 H1N1 influenza in the United States, April-June N. Engl. J. Med. 361: Le, Q. M., Y. Sakai-Tagawa, M. Ozawa, M. Ito, and Y. Kawaoka Selection of H5N1 influenza virus PB2 during replication in humans. J. Virol. 83: Li, Z., et al Molecular basis of replication of duck H5N1 influenza viruses in a mammalian mouse model. J. Virol. 79: Maines, T. R., et al Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325: McAuley, J. L., et al PB1-F2 Proteins from H5N1 and 20 century pandemic influenza viruses cause immunopathology. PLoS Pathog. 6:e Munster, V. J., et al Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 325: Neumann, G., et al Generation of influenza A viruses entirely from cloned cdnas. Proc. Natl. Acad. Sci. U. S. A. 96: Nolan, T., et al Immunogenicity of a monovalent 2009 influenza
6 VOL. 85, 2011 NOTES 4601 A(H1N1) vaccine in infants and children: a randomized trial. JAMA 303: Obenauer, J. C., et al Large-scale sequence analysis of avian influenza isolates. Science 311: Sheng, M., and C. Sala PDZ domains and the organization of supramolecular complexes. Annu. Rev. Neurosci. 24: Shinya, K., et al PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Virology 320: Subbarao, E. K., W. London, and B. R. Murphy A single amino acid in the PB2 gene of influenza A virus is a determinant of host range. J. Virol. 67: Wright, P. F., G. Neumann, and Y. Kawaoka Orthomyxoviruses, p In D. M. Knipe and P. M. Howley (ed.), Fields virology, 5th ed. Lippincott-Raven Publishers, Philadelphia, PA. 26. Yamada, S., et al Biological and structural characterization of a hostadapting amino acid in influenza virus. PLoS Pathog. 6:e Zamarin, D., M. B. Ortigoza, and P. Palese Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice. J. Virol. 80: Zhu, F. C., et al A novel influenza A (H1N1) vaccine in various age groups. N. Engl. J. Med. 361: Zielecki, F., et al Virulence determinants of avian H5N1 influenza A virus in mammalian and avian hosts: role of the C-terminal ESEV motif in the viral NS1 protein. J. Virol. 84:
The M Segment of the 2009 New Pandemic H1N1 Influenza Virus Is Critical for Its High Transmission Efficiency in the Guinea Pig Model
JOURNAL OF VIROLOGY, Nov. 2011, p. 11235 11241 Vol. 85, No. 21 0022-538X/11/$12.00 doi:10.1128/jvi.05794-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. The M Segment of the
More informationCristina Cassetti, Ph.D.
NIAID Extramural Research Update: Recombinant Influenza Viruses and Biosafety Cristina Cassetti, Ph.D. Influenza Program Officer Division of Microbiology and Infectious Diseases NIAID Influenza virus DMID
More informationImportance of 1918 virus reconstruction on current assessments to pandemic risk
Importance of 1918 virus reconstruction on current assessments to pandemic risk Jessica A Belser, PhD Immunology and Pathogenesis Branch Influenza Division Centers for Disease Control and Prevention National
More informationWHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update
WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update 23 July 2009 Introduction This document updates guidance 1 from the World
More informationApplication of Reverse Genetics to Influenza Vaccine Development
NIAID Application of Reverse Genetics to Influenza Vaccine Development Kanta Subbarao Laboratory of Infectious Diseases NIAID, NIH Licensed Vaccines for Influenza Principle: Induction of a protective
More informationEmergence of distinct avian-like influenza A H1N1 viruses in pigs in Ireland and their reassortment with cocirculating H3N2 viruses
International Congress Series 1263 (2004) 209 213 Emergence of distinct avian-like influenza A H1N1 viruses in pigs in Ireland and their reassortment with cocirculating H3N2 viruses Y.P. Lin a, *, M. Bennett
More informationTechnology Overview. Summary
Live Attenuated Influenza Vaccines with Altered NS1 Technology Overview Summary Transformative Technology: Live attenuated influenza vaccines (LAIVs) with precise, genetically stable truncations of the
More informationThe DBA.2 Mouse Is Susceptible to Disease following Infection with a Broad, but Limited, Range of Influenza A and B Viruses
JOURNAL OF VIROLOGY, Dec. 2011, p. 12825 12829 Vol. 85, No. 23 0022-538X/11/$12.00 doi:10.1128/jvi.05930-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. The DBA.2 Mouse Is Susceptible
More informationSupplementary Figure 1 Schematic overview of the mutant virus libraries and their
Supplementary Figure 1 Schematic overview of the mutant virus libraries and their consecutive passages in MDCK cells. All nine virus libraries were passaged twice in MDCK cells. Then, aliquots of all nine
More informationEvolution of influenza
Evolution of influenza Today: 1. Global health impact of flu - why should we care? 2. - what are the components of the virus and how do they change? 3. Where does influenza come from? - are there animal
More informationBlocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model
JOURNAL OF VIROLOGY, Apr. 2009, p. 2803 2818 Vol. 83, No. 7 0022-538X/09/$08.00 0 doi:10.1128/jvi.02424-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Blocking Interhost Transmission
More informationExistence of reassortant A (H1N2) swine influenza viruses in Saitama Prefecture, Japan
International Congress Series 1263 (2004) 749 753 Existence of reassortant A (H1N2) swine influenza viruses in Saitama Prefecture, Japan Shin ichi Shimada a, *, Takayasu Ohtsuka b, Masayuki Tanaka b, Munehito
More informationph1n1 H3N2: A Novel Influenza Virus Reassortment
ph1n1 H3N2: A Novel Influenza Virus Reassortment Jonathan Gubbay Medical Microbiologist Public Health Laboratory Public Health Ontario June 16, 2011 ph1n1 H3N2 Reassortment: Talk Overview Explain strain
More informationLive Attenuated Influenza Vaccine. I. Background and Seasonal Vaccine
Live Attenuated Influenza Vaccine I. Background and Seasonal Vaccine Influenza infection stimulates multiple arms of the immune system Systemic antibody to HA and NA, and multiple internal proteins Mucosal
More informationInfluenza Viruses A Review
Influenza Viruses A Review AVIAN INFLUENZA: INTERSECTORAL COLLABORATION Larnaca, Cyprus 20 22 July 2009 Kate Glynn Scientific and Technical Department, OIE Influenza Viruses C. Goldsmith,1981 Influenza
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature14008 Supplementary Figure 1. Sequence alignment of A/little yellow-shouldered bat/guatemala/060/2010 (H17N10) polymerase with that of human strain A/Victoria/3/75(H3N2). The secondary
More informationPlasmid-Driven Formation of Influenza Virus-Like Particles
JOURNAL OF VIROLOGY, Jan. 2000, p. 547 551 Vol. 74, No. 1 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Plasmid-Driven Formation of Influenza Virus-Like
More informationRelative activity (%) SC35M
a 125 Bat (H17N) b 125 A/WSN (H1N1) Relative activity (%) 0 75 50 25 Relative activity (%) 0 75 50 25 0 Pos. Neg. PA PB1 Pos. Neg. NP PA PB1 PB2 0 Pos. Neg. NP PA PB1 PB2 SC35M Bat Supplementary Figure
More informationStudying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID
Studying Repeated Immunization in an Animal Model Kanta Subbarao Laboratory of Infectious Diseases, NIAID Animal models in Influenza Research Commonly used Mice Ferrets Guinea pigs Non human primates Less
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION doi:10.1038/nature10831 1. Pathological analyses of H5 avian-human reassortant viruses. The rgca04 infection in the lungs of ferrets mainly caused severe bronchopneumonia with
More informationPB1-F2 Amino Acids Regulate Influenza A Viral Polymerase Activity
Journal of Basic & Applied Sciences, 2014, 10, 1-6 1 PB1-F2 Amino Acids Regulate Influenza A Viral Polymerase Activity Yumi Ueda, Motoko Tanaka, Yukihiro Kyan, Mitsutaka Yoshida, Kenji Sasahara and Kyoko
More informationPublic health relevant virological features of Influenza A(H7N9) causing human infection in China
Public health relevant virological features of Influenza A(H7N9) causing human infection in China Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional
More informationSupplementary Figure 1 Weight and body temperature of ferrets inoculated with
Supplementary Figure 1 Weight and body temperature of ferrets inoculated with A/Anhui/1/2013 (H7N9) influenza virus. (a) Body temperature and (b) weight change of ferrets after intranasal inoculation with
More informationSupplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid. HEK293T
More informationSupplemental Information Dose Response Parameters for Gain of Function Pathogens
Supplemental Information Dose Response Parameters for Gain of Function Pathogens Infection Dose-Response To quantify the likelihood of an individual or animal becoming infected from exposure to virus,
More informationInfluenza A Virus Transmission Bottlenecks Are Defined by Infection Route and Recipient Host
Cell Host & Microbe, Volume 16 Supplemental Information Influenza A Virus Transmission Bottlenecks Are Defined by Infection Route and Recipient Host Andrew Varble, Randy A. Albrecht, Simone Backes, Marshall
More informationDevelopment of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine
Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak, PhD Institute of Experimental Medicine, Saint Petersburg, Russia The
More informationPandemic Influenza influenza epidemic: realization of a worst-case scenario
Pandemic Influenza October 9, 2006 1918 influenza epidemic: realization of a worst-case scenario First case: Albert Mitchell, Camp Funston, KS, March 11, 1918 Up to 20% of all humans infected 20-50 million
More information(the change introduced is to add a risk assessment, missing from the previous version, for small-scale laboratory work with characterized CVV)
Update of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza vaccines against avian influenza A(H7N9) virus As of 23 May 2013 (replaces version of 10
More informationTITLE: Influenza A (H7N9) virus evolution: Which genetic mutations are antigenically important?
TITLE: Influenza A (H7N9) virus evolution: Which genetic mutations are antigenically important? AUTHORS: Joshua G. Petrie 1, Adam S. Lauring 2,3 AFFILIATIONS: 1 Department of Epidemiology, University of
More informationIsolation and characterization of H7N9 viruses from live poultry markets Implication of the source of current H7N9 infection in humans
Invited Article Virology doi: 10.7/s11434-013-5873-4 Isolation and characterization of H7N9 viruses from live poultry markets Implication of the source of current H7N9 infection in humans SHI JianZhong
More informationViral genetic determinants of h5n1 influenza viruses that contribute to cytokine dysregulation
Title Viral genetic determinants of h5n1 influenza viruses that contribute to cytokine dysregulation Author(s) Mok, KP; Wong, CHK; Cheung, CY; Chan, MC; Lee, SMY; Nicholls, JM; Guan, Y; Peiris, JSM Citation
More informationPatricia Fitzgerald-Bocarsly
FLU Patricia Fitzgerald-Bocarsly October 23, 2008 Orthomyxoviruses Orthomyxo virus (ortho = true or correct ) Negative-sense RNA virus (complementary to mrna) Five different genera Influenza A, B, C Thogotovirus
More informationMinimal molecular constraints for respiratory droplet transmission of an avian human H9N2 influenza A virus
Minimal molecular constraints for respiratory droplet transmission of an avian human H9N2 influenza A virus Erin M. Sorrell 1, Hongquan Wan 1,2, Yonas Araya, Haichen Song 3, and Daniel R. Perez 4 Department
More informationCharacterization of the 1918 influenza virus polymerase genes
Vol 437 6 October 2005 doi:10.1038/nature04230 Characterization of the 1918 influenza virus polymerase genes Jeffery K. Taubenberger 1, Ann H. Reid 1, Raina M. Lourens 1, Ruixue Wang 1, Guozhong Jin 1
More informationInfluenza Virus Genotypes Circulating In Central Greece During And Vaccine Strain Match
ISPUB.COM The Internet Journal of Microbiology Volume 13 Number 1 Influenza Virus Genotypes Circulating In Central Greece During 2012-2014 And Vaccine Strain Match E Plakokefalos, A Vontas, Z Florou, G
More informationBiological Heterogeneity, Including Systemic Replication in Mice, of H5N1 Influenza A Virus Isolates from Humans in Hong Kong
JOURNAL OF VIROLOGY, Apr. 1999, p. 3184 3189 Vol. 73, No. 4 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Biological Heterogeneity, Including Systemic Replication
More informationREVIEW Cell-mediated Immunity to Influenza Virus Infections: From the Perspective to the Vaccine Development against Highly Pathogenic Avian Influenza
JARQ 42 (4), 245 249 (2008) http://www.jircas.affrc.go.jp REVIEW : From the Perspective to the Vaccine Development against Highly Pathogenic Avian Influenza Hirokazu HIKONO 1 *, Masaji MASE 2, Satoko WATANABE
More informationHost adaptation and transmission of influenza A viruses in mammals
OPEN (2014) 3, e9; doi:10.1038/emi.2014.9 ß 2014 SSCC. All rights reserved 2222-1751/14 www.nature.com/emi REVIEW Host adaptation and transmission of influenza A viruses in mammals Eefje JA Schrauwen and
More informationSupporting Online Material for
www.sciencemag.org/cgi/content/full/328/5985/1529/dc1 Supporting Online Material for Reassortment of Pandemic H1N1/2009 Influenza A Virus in Swine D. Vijaykrishna, L. L. M. Poon, H. C. Zhu, S. K. Ma, O.
More informationMolecular Basis of Replication of Duck H5N1 Influenza Viruses in a Mammalian Mouse Model
JOURNAL OF VIROLOGY, Sept. 2005, p. 12058 12064 Vol. 79, No. 18 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.18.12058 12064.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Molecular
More informationCorrelated mutations in the four influenza proteins essential for viral RNA synthesis, host adaptation, and virulence: NP, PA, PB1, and PB2
Vol.2, No.10, 1138-1147 (2010) http://dx.doi.org/10.4236/ns.2010.210141 Natural Science Correlated mutations in the four influenza proteins essential for viral RNA synthesis, host adaptation, and virulence:
More informationNature Medicine: doi: /nm.4322
1 2 3 4 5 6 7 8 9 10 11 Supplementary Figure 1. Predicted RNA structure of 3 UTR and sequence alignment of deleted nucleotides. (a) Predicted RNA secondary structure of ZIKV 3 UTR. The stem-loop structure
More informationUNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre. Icahn School of Medicine at Mount Sinai, New York
UNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre Icahn School of Medicine at Mount Sinai, New York INFLUENZA VIRUSES PAx B EPIDEMIOLOGY OF HUMAN INFLUENZA VIRUSES A H1N1 H3N2 1968 H2N2 1957 H1N1
More informationUpdate of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines
Update of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines 28 May 2009 Introduction This document updates WHO guidance 1 to national
More informationCurrent Vaccines: Progress & Challenges. Influenza Vaccine what are the challenges?
Current Vaccines: Progress & Challenges Influenza Vaccine what are the challenges? Professor John S. Tam The Hong Kong Polytechnic University Asia-Pacific Alliance for the Control of Influenza (APACI)
More informationCurrent CEIRS Program
History The influenza program at St. Jude has a long, distinguished history as a world-class leader in the study of the origins, evolution, and pathogenesis of influenza viruses. Based on this expertise,
More informationViral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP
Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP 1 Learning Objectives Recognize hazards associated with viral vectors in research and animal
More informationProtein Modeling Event
Protein Modeling Event School Name: School Number: Team Member 1: Team Member 2: : Pre-Build Score: On-Site Build Score: Test Score: Tie Breaker: Total: Final Rank: Part I: Pre-Build (40% of total score)
More informationBioinformation Volume 5
Identification of sequence mutations affecting hemagglutinin specificity to sialic acid receptor in influenza A virus subtypes Usman Sumo Friend Tambunan*, Ramdhan Department of Chemistry, Faculty of Mathematics
More informationA Single N66S Mutation in the PB1-F2 Protein of Influenza A Virus Increases Virulence by Inhibiting the Early Interferon Response In Vivo
JOURNAL OF VIROLOGY, Jan. 2011, p. 652 662 Vol. 85, No. 2 0022-538X/11/$12.00 doi:10.1128/jvi.01987-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. A Single N66S Mutation in
More informationVaccine 30 (2012) Contents lists available at SciVerse ScienceDirect. Vaccine. jou rn al h om epa ge:
Vaccine 30 (2012) 7395 7399 Contents lists available at SciVerse ScienceDirect Vaccine jou rn al h om epa ge: www.elsevier.com/locate/vaccine Possible outcomes of reassortment in vivo between wild type
More informationNS1 Protein Expression in the JaOArS982 Strain of Japanese Encephalitis Virus Does Not Enhance Virulence in Mice
Tropical Medicine and Health Vol. 43 No.4, 2015, 233 237 doi: 10.2149/tmh.2015-27 Copyright 2015 by The Japanese Society of Tropical Medicine 233 Short Communications NS1 Protein Expression in the JaOArS982
More informationInfluenza: Ecology and Continuing Evolution
Influenza: Ecology and Continuing Evolution Robert G. Webster, PhD Division of Virology Department of Infectious Diseases St. Jude Children s s Research Hospital Influenza Virus Negative sense RNA virus
More informationIN VIVO STUDIES ON VIRAL VIRULENCE
IN VIVO STUDIES ON VIRAL VIRULENCE M.Phil student: Emily TSUI Supervisor: Professor Paul K.S Chan Department of Microbiology, CUHK Date: 15th Dec, 2014 Viral Virulence Capacity of a virus to cause disease
More informationSeroepidemiological Evidence of Avian Influenza A Virus Transmission to Pigs in Southern China
JCM Accepts, published online ahead of print on 21 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02625-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Seroepidemiological
More informationAvian Influenza Virus H7N9. Dr. Di Liu Network Information Center Institute of Microbiology Chinese Academy of Sciences
Avian Influenza Virus H7N9 Dr. Di Liu Network Information Center Institute of Microbiology Chinese Academy of Sciences Avian Influenza Virus RNA virus, Orthomyxoviruses Influenza A virus Eight Gene segments
More informationPathogenicity of the Novel A/H7N9 Influenza Virus in Mice
RESEARCH ARTICLE Pathogenicity of the Novel A/H7N9 Influenza Virus in Mice Chris Ka Pun Mok, a,b Horace Hok Yeung Lee, a,b Michael Chi Wai Chan, a Sin Fun Sia, a Maxime Lestra, b John Malcolm Nicholls,
More informationLecture 19 Evolution and human health
Lecture 19 Evolution and human health The evolution of flu viruses The evolution of flu viruses Google Flu Trends data US data Check out: http://www.google.org/flutrends/ The evolution of flu viruses the
More informationFlu, Avian Flu and emerging aspects (H1N1 resistance)
EU-CIS Seminar New trends in Infectious Diseases 26 28 November 2008 / Lyon, France Flu, Avian Flu and emerging aspects (H1N1 resistance) Pr. Florence MORFIN FRE 3011 Université Lyon 1 - CNRS Laboratory
More informationHemagglutinin Mutants of Swine Influenza Virus Differing in
INFECTION AND IMMUNITY, Oct. 1979, p. 197-201 0019-9567/79/10-0197/05$02.00/0 Vol. 26, No. 1 Hemagglutinin Mutants of Swine Influenza Virus Differing in Replication Characteristics in Their Natural Host
More informationInfluenza surveillance and pandemic preparedness - a global challenge Anne Kelso
Influenza surveillance and pandemic preparedness - a global challenge Anne Kelso WHO Collaborating Centre for Reference and Research on Influenza Melbourne, Australia Three global health challenges 243
More informationINFLUENZA-2 Avian Influenza
INFLUENZA-2 Avian Influenza VL 7 Dec. 9 th 2013 Mohammed El-Khateeb Overview 1. Background Information 2. Origin/History 3. Brief overview of genome structure 4. Geographical Distribution 5. Pandemic Nature
More informationC E E Z A D. Rational Development of Influenza Vaccines: NDV-based influenza vaccines for poultry and livestock
C E E Z A D Center of Excellence for Emerging and Zoonotic Animal Diseases A Department of Homeland Security Center of Excellence Rational Development of Influenza Vaccines: NDV-based influenza vaccines
More informationNOTES. The Naturally Attenuated Kunjin Strain of West Nile Virus Shows Enhanced Sensitivity to the Host Type I Interferon Response
JOURNAL OF VIROLOGY, June 2011, p. 5664 5668 Vol. 85, No. 11 0022-538X/11/$12.00 doi:10.1128/jvi.00232-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. NOTES The Naturally Attenuated
More informationInfluenza. Gwen Clutario, Terry Chhour, Karen Lee
Influenza Gwen Clutario, Terry Chhour, Karen Lee Overview Commonly referred to as the flu Defined as a highly contagious viral infection where it starts at the upper respiratory tract and attacks the nose,
More informationUnderstanding mortality from pandemic and seasonal influenza
Understanding mortality from pandemic and seasonal influenza Jonathan A. McCullers Associate Member Department of Infectious Diseases St. Jude Children s Research Hospital H1 H2 H3 H4 H5 H6 H7 H8 H9 H10
More informationInfluenza A and B viruses infect 5 to 15% of the global population
Comparative Study of Influenza Virus Replication in MDCK Cells and in Primary Cells Derived from Adenoids and Airway Epithelium Natalia A. Ilyushina, a Mine R. Ikizler, b Yoshihiro Kawaoka, c,d,e Larisa
More informationSupplementary Figure 1. Prevalence of U539C and G540A nucleotide and E172K amino acid substitutions among H9N2 viruses. Full-length H9N2 NS
Supplementary Figure 1. Prevalence of U539C and G540A nucleotide and E172K amino acid substitutions among H9N2 viruses. Full-length H9N2 NS nucleotide sequences (a, b) or amino acid sequences (c) from
More informationWhat have we learned from H5N1?
What have we learned from H5N1? Ilaria Capua, Calogero (Lillo) Terregino and Giovanni Cattoli OIE/FAO Reference Laboratory for Avian Influenza and OIE Collaborating Center for diseases at the human animal
More informationCross-Reactive T Cells Are Involved in Rapid Clearance of 2009 Pandemic H1N1 Influenza Virus in Nonhuman Primates
Cross-Reactive T Cells Are Involved in Rapid Clearance of 2009 Pandemic H1N1 Influenza Virus in Nonhuman Primates Jason T. Weinfurter 1,2, Kevin Brunner 1, Saverio V. Capuano III 1, Chengjun Li 2, Karl
More informationNature Immunology: doi: /ni Supplementary Figure 1. Infection strategy.
Supplementary Figure 1 Infection strategy. To test the antibody responses against influenza viruses, animals were sequentially infected with two divergent strains of the same subtype. For H1N1 infections,
More informationPalindromes drive the re-assortment in Influenza A
www.bioinformation.net Hypothesis Volume 7(3) Palindromes drive the re-assortment in Influenza A Abdullah Zubaer 1, 2 * & Simrika Thapa 1, 2 1Swapnojaatra Bioresearch Laboratory, DataSoft Systems, Dhaka-15,
More informationShin-Hee Kim, Yongqi Yan, and Siba K. Samal*
JOURNAL OF VIROLOGY, Oct. 2009, p. 10250 10255 Vol. 83, No. 19 0022-538X/09/$08.00 0 doi:10.1128/jvi.01038-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Role of the Cytoplasmic
More informationA Live Attenuated H7N7 Candidate Vaccine Virus Induces Neutralizing Antibody That Confers Protection from Challenge in Mice, Ferrets, and Monkeys
JOURNAL OF VIROLOGY, Nov. 2010, p. 11950 11960 Vol. 84, No. 22 0022-538X/10/$12.00 doi:10.1128/jvi.01305-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. A Live Attenuated H7N7
More informationZoonotic potential of non-avian influenza A viruses
Laboratory of Virology Faculty of Veterinary Medicine Ghent University, Belgium Zoonotic potential of non-avian influenza A viruses Prof. Kristien Van Reeth (1) Several documented cases of influenza virus
More informationSupplementary Fig. 1. Delivery of mirnas via Red Fluorescent Protein.
prfp-vector RFP Exon1 Intron RFP Exon2 prfp-mir-124 mir-93/124 RFP Exon1 Intron RFP Exon2 Untransfected prfp-vector prfp-mir-93 prfp-mir-124 Supplementary Fig. 1. Delivery of mirnas via Red Fluorescent
More informationQinfang Liu, Chuanling Qiao, Henju Marjuki, Bhupinder Bawa, Jingqun Ma, Stephane Guillossou, Richard J. Webby, Jürgen A.
This is the author s final, peer-reviewed manuscript as accepted for publication. The publisher-formatted version may be available through the publisher s web site or your institution s library. Combination
More informationReverse genetic platform for inactivated and live-attenuated influenza vaccine
EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 42, No. 2, 116-121, February 2010 Reverse genetic platform for inactivated and live-attenuated influenza vaccine Eun-Ju Jung, Kwang-Hee Lee and Baik Lin Seong
More informationRecommended composition of influenza virus vaccines for use in the influenza season
Recommended composition of influenza virus vaccines for use in the 2006 2007 influenza season This recommendation relates to the composition of vaccines for the forthcoming influenza season in the northern
More informationIdentification of New Influenza B Virus Variants by Multiplex Reverse Transcription-PCR and the Heteroduplex Mobility Assay
JOURNAL OF CLINICAL MICROBIOLOGY, June 1998, p. 1544 1548 Vol. 26, No. 6 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology Identification of New Influenza B Virus Variants by Multiplex
More informationModeling the Antigenic Evolution of Influenza Viruses from Sequences
Modeling the Antigenic Evolution of Influenza Viruses from Sequences Taijiao Jiang Center of Systems Medicine, Chinese Academy of Medical Sciences Suzhou Institute of Systems Medicine October 8-10, 2015.
More informationPossible Modes of Transmission of Avian Viruses to People: Studies in Experimental Models
Possible Modes of Transmission of Avian Viruses to People: Studies in Experimental Models Jackie Katz and Terry Tumpey Influenza Division CDC, Atlanta, Georgia David E. Swayne USDA/Agricultural Research
More informationImmunopathogenic and Antibacterial Effects of H3N2 Influenza A Virus PB1-F2 Map to Amino Acid Residues 62, 75, 79, and 82
JOURNAL OF VIROLOGY, Dec. 2011, p. 12324 12333 Vol. 85, No. 23 0022-538X/11/$12.00 doi:10.1128/jvi.05872-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Immunopathogenic and
More informationSupplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E,
Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E, TY93/H5N1 GFP-627K, or the TY93/H5N1 PB2(588-759) virus library. To establish our GFP- FACS screening platform, we compared
More informationActive and Passive Immunization for Avian Influenza Virus Infections
NIAID Active and Passive Immunization for Avian Influenza Virus Infections Kanta Subbarao, MD, MPH Laboratory of Infectious Diseases NIAID, NIH Immortalizing H5 HA-Specific Memory B Cells Collection of
More informationExperiences with Live Attenuated Avian Influenza Vaccine Trials in Thailand
Experiences with Live Attenuated Avian Influenza Vaccine Trials in Thailand Punnee Pitisuttithum, MBBS,DTM&H,FRCPT Vaccine Trial Center,Faculty of Tropical Medicine, Mahidol University For MOPH,CDC,MU,Geneva
More informationCharacterization of Uncultivable Bat Influenza Virus Using a Replicative Synthetic Virus
Characterization of Uncultivable Bat Influenza Virus Using a Replicative Synthetic Virus Bin Zhou 1. a, Jingjiao Ma 2., Qinfang Liu 2., Bhupinder Bawa 2, Wei Wang 1, Reed S. Shabman 1, Michael Duff 2,
More informationTrends in influenza A virus genetics: Can we predict the natural evolution of a H5N1 Z?
Current Topics in Virology Vol. 7, 2008 Trends in influenza A virus genetics: Can we predict the natural evolution of a H5N1 Z? Earl G. Brown 1, *, Syed A. Sattar 2, Jason A. Tetro 2 and Jinhua Liu 3 1
More informationEmerging infectious disease: trends in the literature on SARS and H7N9 influenza
Scientometrics (2015) 105:485 495 DOI 10.1007/s11192-015-1681-8 Emerging infectious disease: trends in the literature on SARS and H7N9 influenza Deqiao Tian 1 Tao Zheng 1 Received: 19 July 2015 / Published
More informationNew Small and Versatile Reporter Technologies for Challenging Applications in Virology. Robert Brazas, Ph.D.
New Small and Versatile Reporter Technologies for Challenging Applications in Virology Robert Brazas, Ph.D. Presentation Overview Small size of NanoLuc Luciferase is advantageous Agenda Building a better
More informationReassortment between Avian H5N1 and Human H3N2 Influenza Viruses in Ferrets: a Public Health Risk Assessment
JOURNAL OF VIROLOGY, Aug. 2009, p. 8131 8140 Vol. 83, No. 16 0022-538X/09/$08.00 0 doi:10.1128/jvi.00534-09 Reassortment between Avian H5N1 and Human H3N2 Influenza Viruses in Ferrets: a Public Health
More informationThe A(H7N9) influenza outbreak in China
Viruses in May, Katoomba, 9 11 May 2013 The A(H7N9) influenza outbreak in China Anne Kelso Director WHO Collaborating Centre for Reference and Research on Influenza Melbourne Influenza in the 21 st century:
More informationMultifunctional Adaptive NS1 Mutations Are Selected upon Human Influenza Virus Evolution in the Mouse
Multifunctional Adaptive NS1 Mutations Are Selected upon Human Influenza Virus Evolution in the Mouse Nicole E. Forbes 1,2, Jihui Ping 1,2, Samar K. Dankar 1,2, Jian-Jun Jia 1,2, Mohammed Selman 1,2, Liya
More informationNanoparticulate Vaccine Design: The VesiVax System
Nanoparticulate Vaccine Design: The VesiVax System Gary Fujii, Ph.D. President and CEO Molecular Express, Inc. May 16, 2006 Orlando, Florida Influenza Each year up to 20% of the world's population contracts
More informationSCIENCE CHINA Life Sciences. Environmental connections of novel avian-origin H7N9 influenza virus infection and virus adaptation to the human
SCIENCE CHINA Life Sciences COVER ARTICLE June 2013 Vol.56 No.6: 485 492 doi: 10.1007/s11427-013-4491-3 Environmental connections of novel avian-origin H7N9 influenza virus infection and virus adaptation
More informationHost markers and correlated mutations in the overlapping genes of influenza viruses: M1, M2; NS1, NS2; and PB1, PB1-F2
Vol.2, No.11, 1225-1246 (21) http://dx.doi.org/1.4236/ns.21.21115 Natural Science Host markers and correlated mutations in the overlapping genes of influenza viruses: M1, M2; NS1, NS2; and PB1, PB1-F2
More informationInfluenza vaccines: present and future
PERSPECTIVE SERIES The future of vaccine design Peter Palese and Adolfo García-Sastre, Series Editors Influenza vaccines: present and future Peter Palese and Adolfo García-Sastre Department of Microbiology,
More information1918 Influenza; Influenza A, H1N1. Basic agent information. Section I- Infectious Agent. Section II- Dissemination
1918 Influenza; Influenza A, H1N1 Basic agent information Section I- Infectious Agent Risk Group: - RG3 Synonym or Cross reference: - Spanish Flu - 1918 Flu - El Grippe Characteristics: - SELECT AGENT
More information